The researchers, led by Welmoed K. Van Deen, MD, of the UCLA Center for Inflammatory Bowel Diseases in Los Angeles, developed a monitoring index for remote assessment of disease activity. They validated the index, which is based on patient-reported outcomes, in 301 patients with Crohn’s disease and 265 patients with ulcerative colitis.
Here’s what you need to know:
1. The index assessed activity of Crohn’s disease based on liquid stool frequency, abdominal pain, patient well-being and patient-assessed disease control
2. The index assessed activity of ulcerative colitis based on stool frequency, abdominal pain, rectal bleeding and patient-assessed disease control.
3. Using a scoring system, the index successfully detected both clinical disease activity and endoscopic activity for those with Crohn’s disease and ulcerative colitis.
More articles on gastroenterology and endoscopy:
Biggest hepatology breakthroughs in 2016: Nonalcoholic steatohepatitis, primary biliary cholangitis
ASGE comments on 21st Century Cures Act: 3 notes
Do financial incentives promote patient adherence to CRC screening? 5 study insights
